Introduction
The COVID‐19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.
Aim
To understand how CU patients are affected by the COVID‐19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID‐19.
Materials and Methods
Our cross‐sectional, international, questionnaire‐based, multicenter UCARE COVID‐CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.
Results
The COVID‐19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID‐19 patient care, which negatively impacted on the care of urticaria patients. The rate of face‐to‐face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID‐19, but COVID‐19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID‐19.
Conclusions
The COVID‐19 pandemic brings major changes and challenges for CU patients and their physicians. The long‐term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.
[Epub ahead of print]. 8. Van Gasse AL, Ebo DG, Chiriac AM, et al. The limited value of prolonged drug challenges in nonimmediate amoxicillin (clavulanic acid) hypersensitivity.
We here evaluate allergen immunotherapy guideline (AIT-GL) quality. Only high-quality AIT-GLs should be consulted for AIT management decisions. In low-resource settings, transculturization of these is preferred over developing low-quality guidelines.
Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline ≥2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/month; however, others are still not controlled with 300 mg/month. In these, 150 mg bimonthly could be tried, before up-dosing to 450 mg/month. On the long run (up to 3 years) omalizumab kept its efficacy. In many patients, dosing intervals could be augmented (6-8 weeks, some even more). After a 12-month treatment, about 20% showed long-term remission without relapse. Some biomarkers are being detected. Adjusting omalizumab doses in urticaria patients could enhance efficacy (shortening dosing interval and/or augmenting dose) and save costs (after 12 months: extending dosing interval and/or reducing dose).
We have demonstrated that these patients were allergic to cow's milk, and had circulating and mast cell-bound IgE antibodies specific to cow's milk proteins. We found that the Sabin vaccine contained α-lactalbumin, which may have been responsible for the reactions elicited following vaccination with the Sabin and dual viral vaccines in combination.
BackgroundIn spite of the frequency of chronic urticaria, there are no epidemiological
studies on its prevalence in Argentina.ObjectiveThe objective of this study was to define the prevalence and epidemiological
characteristics of chronic urticaria patients in Buenos Aires.MethodsThe population studied were the members of the Italian Hospital Medical Care
Program, a prepaid health maintenance organization located in the urban
areas around the Autonomous City of Buenos Aires, Argentina. All patients
with diagnosis of chronic urticaria members of the Italian Hospital Medical
Care Program, and with at least 12 months of follow up were included in the
study. All medical records obtained between January 1st, 2012 and December
31, 2014 were analyzed. The prevalence ratio for chronic urticaria per
100,000 population with 95% CI for December 31, 2014 was calculated. The
prevalence rate for the entire population and then discriminated for adults
and pediatric patients (less than 18 years old at diagnosis) was
assessed.Results158,926 members were analyzed. A total of 463 cases of chronic urticaria were
identified on prevalence date (68 in pediatrics, 395 in adults), yielding a
crude point prevalence ratio of 0.29% (CI 95% 0.26-0.31%). The observed
prevalence of chronic urticaria in the adult population was 0.34 % (95% CI
0.31-0.38%), while in pediatrics it was 0.15 % (95% CI 0.11-0.20%).Study limitationsthe main weakness is that the results were obtained from an HMO and therefore
the possibility of selection bias.Conclusionschronic urticaria is a global condition. Its prevalence in Buenos Aires is
comparable with other countries.
Further experimental and clinical studies are needed, with special reference to the time, duration and intensity of exposure to any specific infectious agent which is related to well-defined allergy outcomes. The background information for using microbial products in allergy prevention and treatment is still limited.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.